A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.

Levetiracetam (LEV) is one of the most commonly prescribed antiepileptic drugs, but its mechanism of action is uncertain. Based on prior information that LEV binds to the vesicular protein synaptic vesicle protein 2A and reduces presynaptic neurotransmitter release, we wanted to more rigorously characterize its effect on transmitter release and explain the requirement for a prolonged incubation period for its full effect to manifest. During whole cell patch recordings from rat hippocampal pyramidal neurons in vitro, we found that LEV decreased synaptic currents in a frequency-dependent manner and reduced the readily releasable pool of vesicles. When we manipulated spontaneous activity and stimulation paradigms, we found that synaptic activity during LEV incubation alters the time at which LEV's effect appears, as well as its magnitude. We believe that synaptic activity and concomitant vesicular release allow LEV to enter recycling vesicles to reach its binding site, synaptic vesicle protein 2A. In support of this hypothesis, a vesicular "load-unload" protocol using hypertonic sucrose in the presence of LEV quickly induced LEV's effect. The effect rapidly disappeared after unloading in the absence of LEV. These findings are compatible with LEV acting at an intravesicular binding site to modulate the release of transmitter and with its most marked effect on rapidly discharging neurons. Our results identify a unique neurobiological explanation for LEV's highly selective antiepileptic effect and suggest that synaptic vesicle proteins might be appropriate targets for the development of other neuroactive drugs.

[1]  Eric A. Johnson,et al.  SV2 Mediates Entry of Tetanus Neurotoxin into Central Neurons , 2010, PLoS pathogens.

[2]  Zhen-Yu Zhou,et al.  SV2 Acts via Presynaptic Calcium to Regulate Neurotransmitter Release , 2010, Neuron.

[3]  M. Manfredi,et al.  Intravenous Levetiracetam as first‐line treatment of status epilepticus in the elderly , 2010, Acta neurologica Scandinavica.

[4]  Amy L. Nowack,et al.  Cotrafficking of SV2 and Synaptotagmin at the Synapse , 2010, The Journal of Neuroscience.

[5]  S. Rothman,et al.  Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission , 2009, Seizure.

[6]  R. Kaminski,et al.  Proepileptic phenotype of SV2A‐deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam , 2009, Epilepsia.

[7]  R. Tsien,et al.  The Dynamic Control of Kiss-And-Run and Vesicular Reuse Probed with Single Nanoparticles , 2009, Science.

[8]  T. Südhof,et al.  SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis , 2009, The Journal of Neuroscience.

[9]  J. Gates,et al.  Benzodiazepines in epilepsy: pharmacology and pharmacokinetics , 2008, Acta neurologica Scandinavica.

[10]  Charles F Stevens,et al.  Discharge of the readily releasable pool with action potentials at hippocampal synapses. , 2007, Journal of neurophysiology.

[11]  S. Rothman,et al.  Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission , 2007, Epilepsia.

[12]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[13]  M. Gillard,et al.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. , 2006, European journal of pharmacology.

[14]  O. Gefeller,et al.  Onset of Action of Levetiracetam: A RCT Trial Using Therapeutic Intensive Seizure Analysis (TISA) , 2006, Epilepsia.

[15]  N. S. Austin,et al.  Synaptic Vesicle Protein 2 Enhances Release Probability at Quiescent Synapses , 2006, The Journal of Neuroscience.

[16]  J. McArthur,et al.  Pathology and Quantitation of Cutaneous Innervation , 2005 .

[17]  P. Stanton,et al.  Imaging LTP of presynaptic release of FM1‐43 from the rapidly recycling vesicle pool of Schaffer collateral–CA1 synapses in rat hippocampal slices , 2005, The European journal of neuroscience.

[18]  S. Mochida,et al.  SV2A and SV2C contain a unique synaptotagmin-binding site , 2005, Molecular and Cellular Neuroscience.

[19]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Tsien,et al.  Single synaptic vesicles fusing transiently and successively without loss of identity , 2003, Nature.

[21]  D. Margineanu,et al.  Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. , 2003, European journal of pharmacology.

[22]  Eduardo D. Martín,et al.  Synaptic regulation of the slow Ca2+-activated K+ current in hippocampal CA1 pyramidal neurons: implication in epileptogenesis. , 2001, Journal of neurophysiology.

[23]  J. Cramer,et al.  A systematic review of the safety profile of levetiracetam: a new antiepileptic drug , 2001, Epilepsy Research.

[24]  G. Bernardi,et al.  Levetiracetam does not modulate neuronal voltage-gated Na + and T-type Ca 2+ currents , 2001, Seizure.

[25]  Brian D. Hale,et al.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Sakmann,et al.  Imaging Synaptic Activity in Intact Brain and Slices with FM1-43 in C. elegans, Lamprey, and Rat , 1999, Neuron.

[27]  A. C. Meyer,et al.  Released Fraction and Total Size of a Pool of Immediately Available Transmitter Quanta at a Calyx Synapse , 1999, Neuron.

[28]  M. Whittington,et al.  Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat , 1999, Epilepsy Research.

[29]  Kevin J. Staley,et al.  Presynaptic modulation of CA3 network activity , 1998, Nature Neuroscience.

[30]  S. Beck,et al.  Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[31]  R. Batchelor,et al.  Isoform-specific, Calcium-regulated Interaction of the Synaptic Vesicle Proteins SV2 and Synaptotagmin* , 1996, The Journal of Biological Chemistry.

[32]  Christian Rosenmund,et al.  Definition of the Readily Releasable Pool of Vesicles at Hippocampal Synapses , 1996, Neuron.

[33]  Thomas C. Südhof,et al.  Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25 , 1993, Nature.

[34]  J. Gobert,et al.  ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. , 1992, European journal of pharmacology.

[35]  F. Benfenati,et al.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin , 1992, Nature.

[36]  B. Whaler,et al.  Influence of nerve‐ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin , 1962, The Journal of physiology.

[37]  B. Abou-Khalil.  Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures , 2005, Drug safety.

[38]  P. Patsalos.  Clinical Pharmacokinetics of Levetiracetam , 2004, Clinical pharmacokinetics.

[39]  D. McCormick,et al.  On the cellular and network bases of epileptic seizures. , 2001, Annual review of physiology.

[40]  Silvio O. Rizzoli,et al.  Synaptic Vesicle Pools: An Update , 2010, Front. Syn. Neurosci..